Log in

Relevant bibliographies by topics / TTF Time to failure / Journal articles

To see the other types of publications on this topic, follow the link: TTF Time to failure.

Journal articles on the topic 'TTF Time to failure'

Author: Grafiati

Published: 4 June 2021

Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'TTF Time to failure.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bower, Mark, Paul Fox, Kate Fife, Jas Gill, Mark Nelson, and Brian Gazzard. "HAART PROLONGS TIME TO TREATMENT FAILURE (TTF) IN KAPOSI'S SARCOMA (KS)." JAIDS: Journal of Acquired Immune Deficiency Syndromes 21, no. 1 (1999): A24. http://dx.doi.org/10.1097/00126334-199905010-00078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ozturk, Samet, and Vasilis Fthenakis. "Predicting Frequency, Time-To-Repair and Costs of Wind Turbine Failures." Energies 13, no. 5 (2020): 1149. http://dx.doi.org/10.3390/en13051149.

Full text

Abstract:

Operation and maintenance (O&M) costs, and associated uncertainty, for wind turbines (WTs) is a significant burden for wind farm operators. Many wind turbine failures are unpredictable while causing loss of energy production, and may also cause loss of asset. This study utilized 753 O&M event data from 21 wind turbines operating in Germany, to improve the prediction of failure frequency and associated costs. We applied Bayesian updating to predict wind turbine failure frequency and time-to-repair (TTR), in conjunction to machine learning techniques for assessing costs associated with f

APA, Harvard, Vancouver, ISO, and other styles

3

Thomas, Cornelius Temitope, Olalekan Ogunbiyi, Mudathir Funsho Akorede, and Jimi Benjamin Olufeagba. "Assessment of Failure and Repair Behaviours of the Jebba Hydroelectric Power Station." ELEKTRIKA- Journal of Electrical Engineering 17, no. 3 (2018): 13–19. http://dx.doi.org/10.11113/elektrika.v17n3.113.

Full text

Abstract:

Nigeria power generation is circa 4000 MW as at October 2016, this is far less than the national required value.Jebba Hydroelectric Power Station (JHEPS) is one of the three major hydropower stations in the country which its maximumaverage generation value is still less than the rated value of 578.4 MW. This paper presented some basic concepts of analysisof failure and repair. An algorithm was set up to extract the contiguous set of up-times and down-times to determine time-tofail (TTR) and time-to-repair (TTR) events, these events were analyzed for stochastic study. It was observed that the l

APA, Harvard, Vancouver, ISO, and other styles

4

Fayad, Luis, Barbara Pro, Qi Liu, et al. "Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL)." Blood 106, no. 11 (2005): 933. http://dx.doi.org/10.1182/blood.v106.11.933.933.

Full text

Abstract:

Abstract BACKGROUND: The FLIPI score has been shown to predict survival in FL pts. Previous studies have suggested that type of treatment, and quality of response may not affect survival in pts with stage IV IFL. We address here the significance of TTF and quality of response as prognostic factors for survival in stage IV IFL. METHODS: We reviewed the records of 580 pts with stage IV IFL treated from 1972- to 2002 with anthracycline containing regimens +/− rituximab. Demographics: male 51%, age 60 28%, Hgb<12 17%, high LDH 23%, 5 or more nodal groups 66%, BM+ 93%, FLIPI 3 or more 76%. RESUL

APA, Harvard, Vancouver, ISO, and other styles

5

Pan, Q. F., and Q. Liu. "Poole–Frenkel Emission Saturation and Its Effects on Time-to-Failure in Ta-Ta2O5-MnO2 Capacitors." Advances in Materials Science and Engineering 2019 (December 31, 2019): 1–9. http://dx.doi.org/10.1155/2019/1690378.

Full text

Abstract:

I-V characterization of Ta-Ta2O5-MnO2 capacitors was investigated at different temperatures, and Poole–Frenkel (PF) emission saturation was experimentally observed. Under the saturation voltage, the I-V curves at different temperature converged, and the temperature dependency was vanished. Above the saturation voltage, the leakage current was decreasing as the temperature increased. In order to evaluate the effects of saturation voltages (VS) on time-to-failure (TTF) of the capacitors, VS were first determined at +2°C and +25°C, then voltage accelerating tests were conducted at 85°C under 1.6

APA, Harvard, Vancouver, ISO, and other styles

6

Bigder, Mark G., Sandeep Krishnan, E. Francis Cook, and Anthony M. Kaufmann. "Microsurgical rhizotomy for trigeminal neuralgia in MS patients: technique, patient satisfaction, and clinical outcomes." Journal of Neurosurgery 130, no. 6 (2019): 1877–88. http://dx.doi.org/10.3171/2017.12.jns171647.

Full text

Abstract:

OBJECTIVEPatients with multiple sclerosis (MS)–associated trigeminal neuralgia (TN) have higher recurrence and retreatment rates than non-MS patients. The optimal management strategy and role for microsurgical rhizotomy (MSR) for MS-TN remains to be determined. The aim of this study was to report time to treatment failure (TTF) and pain scores following MSR compared to percutaneous and Gamma Knife procedures.METHODSTime to treatment failure was analyzed after MSR (n = 14) versus prior procedures (n = 53) among MS-TN patients. Kaplan-Meier curves and log-rank test were utilized to compare TTF a

APA, Harvard, Vancouver, ISO, and other styles

7

Stupp, R., A. Kanner, H. Engelhard, et al. "A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma." Journal of Clinical Oncology 28, no. 18_suppl (2010): LBA2007. http://dx.doi.org/10.1200/jco.2010.28.18_suppl.lba2007.

Full text

Abstract:

LBA2007 Background: The NovoTTF is a portable, medical device delivering low intensity, intermediate frequency, alternating electric fields by means of noninvasive, disposable scalp electrodes. These tumor treatment fields (TTF) physically interfere with cell division and assembly of organelles. Methods: Adult pts (KPS≥70%) with recurrent GBM were randomized (stratified by surgery for recurrence and center) to either NovoTTF administered continuously (20-24h/day, 7 days/week) or the best standard chemotherapy (BSC) at each physicians’ discretion. Number of prior therapies was not limited. Prim

APA, Harvard, Vancouver, ISO, and other styles

8

Farkas, Csaba, László Fenyvesi, and Károly Petróczki. "Multiple linear regression model of Golden apple's failure characteristics under repeated compressive load." Potravinarstvo Slovak Journal of Food Sciences 13, no. 1 (2019): 793–99. http://dx.doi.org/10.5219/1168.

Full text

Abstract:

In this paper, the multiple linear regression model of mechanical properties related to the failure mechanism of apple tissue under repeated compressive load was investigated. More refined failure characteristics may lead to improved processing and logistics aspects of the given fruits. For our study, the following failure-related factors are considered during the cyclic measurements of Golden Delicious apples: the viscoelastic parameters, the dissipated energy, and the rupture point of the cell-structure, which is described with the time to failure parameter (TTF). For the determination of vi

APA, Harvard, Vancouver, ISO, and other styles

9

Alexandre, J., P. Bleuzen, J. Bonneterre, et al. "Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients." Journal of Clinical Oncology 18, no. 3 (2000): 562. http://dx.doi.org/10.1200/jco.2000.18.3.562.

Full text

Abstract:

PURPOSE: To identify predictive factors for efficacy and safety in advanced breast cancer (ABC) patients treated in the French compassionate-use docetaxel program. PATIENTS AND METHODS: A total of 825 ABC patients treated with docetaxel (100 mg/m2 every 3 weeks) were source-reviewed and analyzed for prognostic factors associated with overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), febrile neutropenia, mucositis, and severe fluid retention syndrome by univariate and multivariate analysis. RESULTS: The ORR was 22.9% (95% confidence interval, 20.2% to 26.2%).

APA, Harvard, Vancouver, ISO, and other styles

10

Hochmair, Maximilian J., Alessandro Morabito, Desiree Hao, et al. "Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study." Future Oncology 15, no. 25 (2019): 2905–14. http://dx.doi.org/10.2217/fon-2019-0346.

Full text

Abstract:

Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8–46.3) overall and 45.7 months (90% CI: 45.3–51.5) in patients with Del19-positive tumors (n = 149); 2-year survival w

APA, Harvard, Vancouver, ISO, and other styles

11

Ito, Kentaro, Takeharu Yamanaka, Satomi Watanabe, et al. "The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)." Journal of Clinical Oncology 37, no. 15_suppl (2019): 9038. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9038.

Full text

Abstract:

9038 Background: Previous clinical trials demonstrated that alectinib (ALEC) had a longer time-to-progression than crizotinib (CRZ) in 1st-line settings. Information on long-term overall survival (OS), however, is still limited with a few studies having reported that the sequential strategy of “CRZ followed by other ALK-inhibitor” can provide extended OS. In Japan, ALEC was approved for a 1st-line setting earlier than in other countries. Methods: We reviewed the clinical data of ALK-rearranged NSCLC patients who received CRZ or ALEC between May 2012 and Dec 2016. Patients were divided into two

APA, Harvard, Vancouver, ISO, and other styles

12

Fullerton, Madison M., Louis Passfield, Martin J. MacInnis, Danilo Iannetta, and Juan M. Murias. "Prior exercise impairs subsequent performance in an intensity- and duration-dependent manner." Applied Physiology, Nutrition, and Metabolism 46, no. 8 (2021): 976–85. http://dx.doi.org/10.1139/apnm-2020-0689.

Full text

Abstract:

Prior constant-load exercise performed for 30-min at or above maximal lactate steady state (MLSSp) significantly impairs subsequent time-to-task failure (TTF) compared with TTF performed without prior exercise. We tested the hypothesis that TTF would decrease in relation to the intensity and the duration of prior exercise compared with a baseline TTF trial. Eleven individuals (6 males, 5 females, aged 28 ± 8 yrs) completed the following tests on a cycle ergometer (randomly assigned after MLSSp was determined): (i) a ramp-incremental test; (ii) a baseline TTF trial performed at 80% of peak powe

APA, Harvard, Vancouver, ISO, and other styles

13

Horvat, Troy Z., Nelly G. Adel, Thu-Oanh Dang, et al. "Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center." Journal of Clinical Oncology 33, no. 28 (2015): 3193–98. http://dx.doi.org/10.1200/jco.2015.60.8448.

Full text

Abstract:

Purpose Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab treatment outside of clinical trials to determine the frequency of use of systemic corticosteroid or anti-tumor necrosis factor α (anti-TNFα) therapy and the effect of these therapies on overall survival (OS) and time to treatment failure (TTF). Patients and Methods We reviewed retrospectively the medical records of patients with melanoma who had received treatment between April 2011 and July 2

APA, Harvard, Vancouver, ISO, and other styles

14

Bigder, M., S. Krishnan, EF Cook, and AM Kaufmann. "P.023 Clinical and patient satisfaction outcomes after partial sensory rhizotomy for refractory trigeminal neuralgia among MS patients." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 45, s2 (2018): S21. http://dx.doi.org/10.1017/cjn.2018.125.

Full text

Abstract:

Background: MS related trigeminal neuralgia (MS-TN) is associated with high recurrence and retreatment rates. Optimal treatment and role for partial sensory rhizotomy (PSR) for MS-TN remains to be determined. Methods: We analyzed time to treatment failure (TTF) after PSR (n=14) versus other prior procedures (n=53) among 12 consecutively treated MS-TN patients. Kaplan-Meier curves and Log-Rank tests were utilized to compare BNI pain scores and TTF after PSR vs prior procedures using the same patient cohort as their own control group. Subsequent analysis compared TTF after PSR to other procedure

APA, Harvard, Vancouver, ISO, and other styles

15

Sugiyama, Keiji, Kazuhiro Shiraishi, Takuya Motohashi, et al. "The impact of nutrition support in advanced gastric adenocarcinoma patients treated with chemotherapy." Journal of Clinical Oncology 39, no. 3_suppl (2021): 208. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.208.

Full text

Abstract:

208 Background: Numerous studies have demonstrated how malnutrition and cachexia are associated with poor survival in advanced gastric cancer (AGC). The impact of nutrition support involving multidisciplinary specialists is unclear, particularly among patients with AGC being treated with chemotherapy. This study aimed to clarify the differences in patient characteristics and survival outcomes between patients receiving nutrition support (NS) and routine care (RC). Methods: We retrospectively analyzed 212 consecutive patients with AGC at a single institution between January 2015 and June 2020.

APA, Harvard, Vancouver, ISO, and other styles

16

Dranitsaris, George, Debu Tripathy, Nancy L. Beegle, Traci L. Kalberer, John David Cox, and Claudio Faria. "Real-world analysis of eribulin in metastatic breast cancer (MBC): An assessment of time to treatment failure (TTF) in a community oncology setting." Journal of Clinical Oncology 31, no. 26_suppl (2013): 174. http://dx.doi.org/10.1200/jco.2013.31.26_suppl.174.

Full text

Abstract:

174 Background: There have been important advances in the treatment of patients with MBC. However, certain patient subgroups such as whose who are triple negative remain a therapeutic challenge. Eribulin is the newest cytotoxic to gain regulatory approval for MBC in the Unites States. In this analysis, the safety and efficacy of eribulin in TNBC patients and those with prior anthracycline exposure were assessed in an early cohort treated in a U.S. community oncology setting. Methods: Ninety patients treated in eight community oncology clinics across the U.S. were identified. Patients were foll

APA, Harvard, Vancouver, ISO, and other styles

17

Doshi, Gurjyot K., Mairead Kearney, Murtuza Bharmal, et al. "SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): Influence of treatment sequencing on time to treatment failure and overall survival in the United States." Journal of Clinical Oncology 37, no. 7_suppl (2019): 453. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.453.

Full text

Abstract:

453 Background: With the introduction of immunotherapy (IO) for locally advanced or metastatic urothelial carcinoma (mUC), optimal treatment sequence should be considered. This study aimed to compare time to treatment failure (TTF) and overall survival (OS) among these patients (pts) treated with first-line (1L) systemic chemotherapy followed by second-line (2L) IO ( C-IO) vs 1L and 2L chemotherapy ( C-C) sequence within the US community oncology Network (USON). Methods: This was a retrospective study of adult locally advanced or mUC pts who initiated systemic therapy between 1/1/15 – 4/30/17

APA, Harvard, Vancouver, ISO, and other styles

18

Zhang, Yuan Xiang, Jun Wu, and Ying Yu Ji. "Prediction of Electromigration Induced Void and Hillock for IC Interconnect Structures." Key Engineering Materials 546 (March 2013): 6–11. http://dx.doi.org/10.4028/www.scientific.net/kem.546.6.

Full text

Abstract:

This paper investigates the electromigration (EM) induced void and hillock generation in IC interconnect structures. The driving force for electromigration induced failure considered here includes the electron wind force, stress gradient, temperature gradient, as well as the atomic density gradient, which were neglected in many of the existing studies on eletromigration. The comparison of void/hillock formation and the time to failure (TTF) life through numerical example of the SWEAT structure with the measurement results are studied and discussed.

APA, Harvard, Vancouver, ISO, and other styles

19

Signorovitch, James E., Nicholas J. Vogelzang, Sumanta Kumar Pal, et al. "Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews." Journal of Clinical Oncology 31, no. 15_suppl (2013): e15504-e15504. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e15504.

Full text

Abstract:

e15504 Background: Second-line targeted therapies for metastatic renal cell carcinoma (mRCC) include mammalian target of rapamycin (mTOR) inhibitors and tyrosine kinase inhibitors (TKIs). This study aimed to compare practice-based effectiveness of these therapies in a recent chart review, and to compare findings with a previous chart review (Yang et al., 2012. ASCO). Methods: Community-based medical oncologists/hematologists (N=36) reviewed charts for ≤ 15 patients each. Included patients were aged ≥ 18 years, received a 1st-line TKI and initiated 2nd-line targeted therapy in 2010 or later. Th

APA, Harvard, Vancouver, ISO, and other styles

20

Cowling, Brianna L., Brad Harwood, David B. Copithorne, and Charles L. Rice. "Rate modulation of human anconeus motor units during high-intensity dynamic elbow extensions." Journal of Applied Physiology 121, no. 2 (2016): 475–82. http://dx.doi.org/10.1152/japplphysiol.00131.2016.

Full text

Abstract:

Investigations of high-intensity isometric fatiguing protocols report decreases in motor unit firing rates (MUFRs), but little is known regarding changes in MUFRs following fatigue induced by high-intensity dynamic contractions. Our purpose was to evaluate MUFRs of the anconeus (an accessory elbow extensor) and elbow extension power production as a function of time to task failure (TTF) during high-velocity fatiguing concentric contractions against a moderately heavy resistance. Fine-wire intramuscular electrode pairs were inserted into the anconeus to record MUs in 12 male participants (25 ±

APA, Harvard, Vancouver, ISO, and other styles

21

Bauer, David R., John M. Baldwin, and Kevin R. Ellwood. "Correlation of Laboratory Tire Endurance and Rubber Aging." Rubber Chemistry and Technology 80, no. 4 (2007): 726–37. http://dx.doi.org/10.5254/1.3548190.

Full text

Abstract:

Abstract Tire endurance as measured by performance on the National Highway Traffic Safety Administration (NHTSA) Stepped Up Load (SUL) test is shown to be a function of both tire construction and the extent of oxidation in the skim and wedge rubber regions of the tire, as measured by peel strength or elongation to break retention. Tire constructions can be distinguished by speed rating. Tires with higher speed ratings (&gt; S) tend to have relatively high times-to-failure (TTF) in the SUL test and are relatively insensitive to rubber oxidation. SUL TTFs for tires with speed rating of S and

APA, Harvard, Vancouver, ISO, and other styles

22

Burnette, Brian L., Gregory Wiseman, Thomas M. Habermann, et al. "Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy." Blood 118, no. 21 (2011): 1640. http://dx.doi.org/10.1182/blood.v118.21.1640.1640.

Full text

Abstract:

Abstract Abstract 1640 Background: The introduction of radioimmunotherapy (RIT) into clinical practice for the treatment of follicular lymphoma (FL) occurred at a time at which many patients did not have prior exposure to rituximab. Clinical trials in the relapsed/refractory setting, as well as consolidation in the upfront setting have included a small number of patients that had been previously treated with rituximab or a rituximab containing treatment regimen. We evaluated the effect of prior rituximab therapy on the efficacy of RIT. METHODS: The prospective lymphoma database was queried for

APA, Harvard, Vancouver, ISO, and other styles

23

Alix-Fages, Romero-Arenas, Castro-Alonso, et al. "Short-Term Effects of Anodal Transcranial Direct Current Stimulation on Endurance and Maximal Force Production. A Systematic Review and Meta-Analysis." Journal of Clinical Medicine 8, no. 4 (2019): 536. http://dx.doi.org/10.3390/jcm8040536.

Full text

Abstract:

The purpose of the present systematic review and meta-analysis was to explore the effects of transcranial direct current stimulation (tDCS) on endurance (i.e., time to task failure (TTF)) and maximal voluntary contraction (MVC). Furthermore, we aimed to analyze whether the duration of stimulation, the brain region targeted for stimulation, and the task performed could also influence motor performance. We performed a systematic literature review in the databases MEDLINE and Web of Science. The short-term effects of anodal tDCS and sham stimulation (placebo) were considered as experimental and c

APA, Harvard, Vancouver, ISO, and other styles

24

Marshall, Shoko, Kenji Nakano, Yoshiya Sugiura, et al. "Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution." Sarcoma 2018 (2018): 1–7. http://dx.doi.org/10.1155/2018/8926598.

Full text

Abstract:

Background. Doxorubicin is the key drug for treatment of advanced soft tissue sarcoma (STS). The appropriate dosage of doxorubicin, regarding monotherapy or the role of combination therapy, is unclear. Methods. We retrospectively reviewed patients with advanced or metastatic STS of nonextremities who were treated with doxorubicin-based chemotherapies in our institution. Time to treatment failure (TTF), overall survival (OS), overall response, and prognostic factors for OS were evaluated. Results. Seventy-five patients were enrolled. The median TTF was 4.7 months, and the median OS was 20.1 mon

APA, Harvard, Vancouver, ISO, and other styles

25

Sridhara, Rajeshwari, Jiaxi Zhou, Marc Robert Theoret, and Pallavi Shruti Mishra-Kalyani. "Time to treatment failure (TTF) as a potential clinical endpoint in real-world evidence (RWE) studies of melanoma." Journal of Clinical Oncology 36, no. 15_suppl (2018): 9578. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.9578.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Yang, Chih-Hsin, Chong-Jen Yu, Jin-Yuan Shih, et al. "SpecificEGFRMutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy." Journal of Clinical Oncology 26, no. 16 (2008): 2745–53. http://dx.doi.org/10.1200/jco.2007.15.6695.

Full text

Abstract:

PurposeTo explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non–small-cell lung cancer (NSCLC) patients receiving gefitinib treatment.Patients and MethodsWe designed a phase II study to test gefitinib antitumor efficacy in advanced-stage, chemotherapy-naive NSCLC patients. Patients were treated with gefitinib 250 mg/d. Tumor assessments were performed every 2 months. Responding or stable patients were treated until progression or unacceptable toxicity. All scans were reviewed independently. EGFR exons 18-21 sequence, K-ras exon 2 sequence, and MET gene copy n

APA, Harvard, Vancouver, ISO, and other styles

27

Buske, Christian, Eva Hoster, Martin Dreyling, Joerg Hasford, Michael Unterhalt, and Wolfgang Hiddemann. "The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome." Blood 108, no. 5 (2006): 1504–8. http://dx.doi.org/10.1182/blood-2006-01-013367.

Full text

Abstract:

The Follicular Lymphoma International Prognostic Index (FLIPI) was developed to predict prognosis of patients with follicular lymphoma (FL). However, it was based on different protocols, none of which included rituximab. The current analysis aimed at evaluating the predictive value of the FLIPI for treatment outcome in 362 patients with advanced-stage FL treated front-line with rituximab/CHOP in a prospective trial of the German Low Grade Lymphoma Study Group. According to the FLIPI, 14% of the patients were classified as low-risk, 41% as intermediate-risk, and 45% as high-risk patients. With

APA, Harvard, Vancouver, ISO, and other styles

28

Kalaiselvan, C., and Lokavarapu Bhaskara Rao. "Highly Accelerated Life Testing of Ceramic Capacitors Using Capacitor Test Board by Lognormal Method and Integrated with PLM Solutions." Advanced Science Letters 24, no. 8 (2018): 5859–65. http://dx.doi.org/10.1166/asl.2018.12210.

Full text

Abstract:

Compare to previous decay, now days consumer expectation is very high about the electronic product what they are going to purchase. The consumer analyzes the quality of the product with the product competitors. The electronic component manufacturer is under immersive pressure to show their reliability of their product and maintain their place in the market. Reliability engineering helps to announce the guaranty period of the electronic product. Highly Accelerated Life Testing (HALT) is the latest technology in the reliability field for testing the electronic components. The highly accelerated

APA, Harvard, Vancouver, ISO, and other styles

29

Friedman, Claire Frances, Jedd D. Wolchok, Michael Andrew Postow, et al. "Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors." Journal of Clinical Oncology 35, no. 7_suppl (2017): 100. http://dx.doi.org/10.1200/jco.2017.35.7_suppl.100.

Full text

Abstract:

100 Background: The combination of nivolumab and ipilimumab (nivo+ipi) prolongs progression-free survival in treatment-naïve patients (pts) with advanced melanoma. However, the efficacy and tolerability of nivo+ipi in pts previously treated with checkpoint blockade inhibitors (CPI) are unknown. Methods: 19 pts previously treated with CPI (ipi or anti-PD-1 as single agents) were treated with nivo+ipi at MSKCC. Ipi (3mg/kg) and nivo (1mg/kg) were administered q3 weeks for 4 doses with the option to continue anti-PD1 maintenance. Pts were followed for time to treatment failure (TTF), defined as t

APA, Harvard, Vancouver, ISO, and other styles

30

Falkson, G., R. Gelman, C. I. Falkson, J. Glick, and J. Harris. "Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study." Journal of Clinical Oncology 9, no. 12 (1991): 2153–61. http://dx.doi.org/10.1200/jco.1991.9.12.2153.

Full text

Abstract:

Six hundred twenty-four women with metastatic breast cancer were entered on Eastern Cooperative Oncology Group (ECOG) study EST 2181. Patients were treated with mitolactol, doxorubicin, vincristine (DAV), tamoxifen, and fluoxymesterone (DAVTH). Nine patients were canceled, and 114 were ineligible (half because of concomitant diseases). Among the 501 eligible patients, the overall response rate was 54% (14% complete response and 5% not assessable). The median time to treatment failure (TTF) was 9.0 months, and the median survival was 20.9 months. Multivariate models were fit on a randomly chose

APA, Harvard, Vancouver, ISO, and other styles

31

Jones, Carissa, Rebecca Lachs, Emma Sturgill, et al. "Real-world data evaluating immunotherapy markers and checkpoint inhibitor response among GI cancers in a large community-based oncology network." Journal of Clinical Oncology 39, no. 3_suppl (2021): 113. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.113.

Full text

Abstract:

113 Background: Checkpoint inhibitor (CPI) therapies have shown prolonged survival in patients (pts) with microsatellite instability (MSI). Tumor mutation burden (TMB) has also been associated with benefit from CPIs, with pembrolizumab recently approved for solid tumors with a TMB of ≥10 muts/mb. However, the validity of a tissue-agnostic approach has been debated given the high degree of TMB variation across tumor types. We sought to evaluate the impact of TMB and MSI on CPI response in pts with advanced gastrointestinal (GI) cancers who received NGS profiling. Methods: Patients within the Sa

APA, Harvard, Vancouver, ISO, and other styles

32

Yamashita, Toshinari, Yutaka Yamamoto, Mutsuko Ibusuki, et al. "Subsequent endocrine therapy after resistance to ethinylestradiol treatment for the late-stage metastatic breast cancer: A retrospective cohort study." Journal of Clinical Oncology 32, no. 26_suppl (2014): 148. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.148.

Full text

Abstract:

148 Background: Aromatase inhibitor (AI) is a most commonly used as the endocrine therapy in postmenopausal hormone-dependent breast cancer. Paradoxically, estrogen additive therapy using ethinylestradiol can be useful after long-term estrogen deprivation therapies with AI. Furthermore, there is a possibility of the beneficial effect of AI or fulvestrant as a subsequent endocrine therapy after EE2 failure. Methods: Ethinylestradiol (EE2; 3mg/day, TID) therapy was performed in 20 patients with metastatic breast cancer (median; 62 years-old, the mean observation time: 13.6 months.), who were hea

APA, Harvard, Vancouver, ISO, and other styles

33

Hitt, R., J. J. Grau, A. Lopez-Pousa, et al. "Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC)." Journal of Clinical Oncology 27, no. 15_suppl (2009): 6009. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.6009.

Full text

Abstract:

6009 Background: Induction chemotherapy (IC) with TPF isa standard regimen for patients (pts) with locally advanced head and neck squamous cell carcinoma (N Engl J Med. 2007;357:1705–1715). However, CRT alone is standard treatment for unresectable LAHNC. We designed a trial to compare two different regimens of IC followed by CRT versus CRT alone in pts with unresectable LAHNC. Methods: Pts with unresectable, measurable LAHNC, adequate organ function, and ECOG 0–1 were enrolled and stratified according to primary tumor site. (IC) regimens (3 cycles): PF (cisplatin 100 mg/m2 day [d] 1, then 5-FU

APA, Harvard, Vancouver, ISO, and other styles

34

Liu, Haiyun, Yanfeng Li, Guangquan Chai, et al. "Effect of synchronous irrigation on cyclic fatigue of nickel-titanium instrument in the dynamic and static models." Journal of Applied Biomaterials & Functional Materials 19 (January 2021): 228080002098740. http://dx.doi.org/10.1177/2280800020987403.

Full text

Abstract:

Objective: To evaluate the effect of synchronous water irrigation on the fatigue resistance of nickel-titanium instrument. Methods: A standardized cyclic fatigue test models were established, and five types of nickel-titanium instruments (PTU F1, WO, WOG, RE, and M3) were applied. Each instrument was randomly divided into two groups ( N = 12). There was synchronous water irrigation in the experimental group, and no water irrigation in the control group. Besides, ProTaper Universal F1 was randomly divided into 10 groups ( N = 20). In the static group, nickel-titanium instruments were divided in

APA, Harvard, Vancouver, ISO, and other styles

35

Bhindi, Bimal, Jeffrey Graham, Connor Wells, et al. "Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib." Journal of Clinical Oncology 37, no. 15_suppl (2019): 4578. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4578.

Full text

Abstract:

4578 Background: While the CARMENA trial prompts more caution with upfront cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC), 17% of patients in the sunitinib alone arm underwent deferred CN (dCN). Upfront systemic therapy has been proposed as a potential litmus test to identify patients suitable for CN, but data on outcomes are limited. We sought to characterize outcomes of dCN after upfront sunitinib relative to sunitinib alone. Methods: Patients with newly diagnosed mRCC receiving upfront sunitinib were identified from the International mRCC Database Con

APA, Harvard, Vancouver, ISO, and other styles

36

Zhang, Hanbo, Naveen S. Basappa, Sunita Ghosh, et al. "Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)." Kidney Cancer 5, no. 1 (2021): 21–29. http://dx.doi.org/10.3233/kca-210110.

Full text

Abstract:

BACKGROUND: Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that has demonstrated efficacy in metastatic renal-cell carcinoma (mRCC) randomized trials. OBJECTIVE: To explore the real-world effectiveness of cabozantinib in pretreated patients with mRCC, including patients who progressed on immune-oncology checkpoint inhibitor (ICI) therapy. METHODS: Using the Canadian Kidney Cancer information system (CKCis), patients with mRCC treated with cabozantinib monotherapy as second-line or later from January 1, 2011 to September 1, 2019 were identified. Patients were stratified b

APA, Harvard, Vancouver, ISO, and other styles

37

Laufman, L. R., R. M. Bukowski, M. A. Collier, et al. "A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer." Journal of Clinical Oncology 11, no. 10 (1993): 1888–93. http://dx.doi.org/10.1200/jco.1993.11.10.1888.

Full text

Abstract:

PURPOSE A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer. PATIENTS AND METHODS A double-blind, placebo-controlled trial design was used to eliminate observer bias. An escalating FU dosing schedule was used to achieve equal toxicity. End points were response, time to treatment failure (TTF), and eight quality-of-life (QL) parameters. A crossover arm allowed FU-treated patients to receive FU-LV combination treatment

APA, Harvard, Vancouver, ISO, and other styles

38

Ma, L., K. L. Stevinson, T. A. Burke, and S. Kumar. "Overall survival (OS) and time to failure (TTF) associated with anti-myeloma therapy in a U.S. managed-care population." Journal of Clinical Oncology 28, no. 15_suppl (2010): e18505-e18505. http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e18505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Buckley, Tyler Howard, Anitha Alex, James M. Farnham, et al. "Association of single nucleotide polymorphisms (SNPs) in SULT1E1 with response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC)." Journal of Clinical Oncology 34, no. 2_suppl (2016): 222. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.222.

Full text

Abstract:

222 Background: Germline variations in genes involved in androgen biosynthesis and metabolic pathways may predict response to AA in men with mCRPC, serve as prognostic and predictive biomarkers, and guide towards more individualized therapy. Methods: 836 single nucleotide polymorphisms (SNPs) from the Illumina OmniExpress genotyping platform within the boundaries of 61 genes reported to be involved in the androgen metabolic pathway were investigated for association with time to treatment failure (TTF) in 68 Caucasian men with mCRPC undergoing treatment with AA. Cox proportional hazard analysis

APA, Harvard, Vancouver, ISO, and other styles

40

Falkson, C. I., J. Ibrahim, J. M. Kirkwood, A. S. Coates, M. B. Atkins, and R. H. Blum. "Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study." Journal of Clinical Oncology 16, no. 5 (1998): 1743–51. http://dx.doi.org/10.1200/jco.1998.16.5.1743.

Full text

Abstract:

PURPOSE To investigate the response rate, time to treatment failure (TTF), overall survival, and toxicity in patients with metastatic melanoma treated with dacarbazine alone, dacarbazine plus interferon (IFN), dacarbazine plus tamoxifen (TMX), or dacarbazine plus IFN plus TMX. MATERIALS AND METHODS Two hundred seventy-one patients (258 were eligible) were randomized in a 2 x 2 factorial design to receive one of the above treatments. The trial was designed to detect a 50% improvement in survival with 83% power. RESULTS Nine complete (CRs) and 18 partial responses (PRs) were observed in the pati

APA, Harvard, Vancouver, ISO, and other styles

41

Yip, Steven, Jeenan Kaiser, Haocheng Li, Scott A. North, Daniel Yick Chin Heng, and Nimira S. Alimohamed. "Real world outcomes in advanced urothelial cancer and the role of neutrophil to lymphocyte ratio." Journal of Clinical Oncology 35, no. 15_suppl (2017): e16020-e16020. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16020.

Full text

Abstract:

e16020 Background: Advanced urothelial carcinoma (UC) patients have a poor prognosis. In the first and second line UC treatment setting, we investigated real world outcomes and evaluated the prognostic role of the neutrophil to lymphocyte ratio (NLR). Methods: A retrospective analysis was performed on advanced UC patients treated with systemic therapy. Overall response rates (ORR), time to treatment failure (TTF) and overall survival (OS) were calculated. Cox regression analysis was performed to examine the association between baseline NLR (low NLR<3 vs high NLR≥3) and TTF and OS. Results:

APA, Harvard, Vancouver, ISO, and other styles

42

Zhao, Yan, Gregory Russell Pond, Gurudatta Naik, Xiao X. Wei, Bradley Alexander McGregor, and Guru Sonpavde. "C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy." Journal of Clinical Oncology 36, no. 6_suppl (2018): 436. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.436.

Full text

Abstract:

436 Background: Clinical prognostic factors have been reported for patients receiving systemic chemotherapy. We hypothesized that markers of tissue damage and inflammation may be prognostic. We conducted a retrospective study to evaluate the prognostic impact of serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) in patients with metastatic UC. Methods: We collected data for patients with metastatic UC receiving systemic therapy and measured serum LDH and CRP at baseline before initiating therapy. The variables collected were recognized clinical prognostic factors (performance statu

APA, Harvard, Vancouver, ISO, and other styles

43

Vilbert, Maysa Tamara Silveira, Natasha Carvalho Pandolfi, Marcelle Goldner Cesca, et al. "A web app nomogram based on real-life patients: Guide decision in first-line treatment for metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 38, no. 15_suppl (2020): e17538-e17538. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e17538.

Full text

Abstract:

e17538 Background: mCRPC phenotype involves androgen-receptor signalling mechanisms that support the use of abiraterone/enzalutamide (Abi/Ez). These therapies improve overall survival (OS) and quality-of-life, with a favourable safety profile. There is no validated data defining the best drug or sequence to be used. Methods: A retrospective study evaluated if a nomogram helps the decision-making of first-line for mCRPC. The nomogram evaluated time-to-treatment failure (TTF) from Abi/Ez and Docetaxel (Doc) treatment and had C-índex of 0.726. Time from start of androgen deprivation therapy to Ab

APA, Harvard, Vancouver, ISO, and other styles

44

Vogel, C. L., I. Shemano, J. Schoenfelder, R. A. Gams, and M. R. Green. "Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer." Journal of Clinical Oncology 11, no. 2 (1993): 345–50. http://dx.doi.org/10.1200/jco.1993.11.2.345.

Full text

Abstract:

PURPOSE To explore further the efficacy of high-dose toremifene in patients with advanced breast cancer who had failed to respond to tamoxifen or whose disease had progressed on tamoxifen. PATIENTS AND METHODS One hundred two perimenopausal or postmenopausal women with metastatic breast cancer refractory to tamoxifen were entered onto a phase II clinical trial of toremifene at a dose of 200 mg/d. The study patients consisted of 28 primarily refractory patients; 43 patients who had relapsed after a prior tamoxifen response; and 31 patients who had relapsed while receiving adjuvant tamoxifen. Th

APA, Harvard, Vancouver, ISO, and other styles

45

Silveira Vilbert, Maysa Tamara, Natasha Carvalho Pandolfi, Marcelle Goldner Cesca, et al. "Biomarkers of prolonged time to treatment failure in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A real life patients-based nomogram and web app." Journal of Clinical Oncology 38, no. 6_suppl (2020): 202. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.202.

Full text

Abstract:

202 Background: Survival outcomes for metastatic castration resistant prostate cancer (mCRPC) patients (pts) have greatly improved following the approval of Docetaxel and abiraterone(Abi)/enzalutamide(Ez). However, it is not clear who is likely to benefit more from these therapies in real life clinical practice. Methods: A retrospective cohort study was performed with mCRPC pts treated with Abi/Ez in pre-Docetaxel setting. Primary endpoint: to identify predictive biomarkers of long time to treatment failure (TTF), develop a nomogram and convert it into a web app. Secondary endpoint: to correla

APA, Harvard, Vancouver, ISO, and other styles

46

Chawla, Anita, Filip Janku, Jennifer J. Wheler, et al. "Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study." JCO Precision Oncology, no. 2 (November 2018): 1–11. http://dx.doi.org/10.1200/po.18.00074.

Full text

Abstract:

Purpose Comprehensive genomic profiling (CGP) detects several classes of genomic alterations across numerous genes simultaneously and can match more patients with genomically targeted therapies than conventional molecular profiling. The current study estimated the costs of anticancer drugs and overall survival (OS) for patients who were treated with matched and unmatched therapy. Methods Costs were estimated for patients with complete data (188 of 500 patients) from a prospective, nonrandomized study of patients with diverse refractory cancers who underwent CGP and were treated with matched or

APA, Harvard, Vancouver, ISO, and other styles

47

Phatak, Hemant, Shivani Pandya, Ting Yu, et al. "Real-world clinical and economic outcomes among newly-diagnosed merkel cell carcinoma (MCC) patients initiating first-line (1L) checkpoint inhibitors (CPIs) or chemotherapy (CT) in the veterans health administration (VHA)." Journal of Clinical Oncology 37, no. 15_suppl (2019): e21002-e21002. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e21002.

Full text

Abstract:

e21002 Background: The use of CPIs among patients (pts) with metastatic MCC, a rare and aggressive skin cancer, has increased since the US FDA approval of avelumab and the National Cancer Comprehensive Network (NCCN) recommendation of CPIs in 2017. Given the growing interest in understanding real-world clinical and economic outcomes associated with CPI use, this study assessed time to treatment failure (TTF), overall survival (OS), healthcare resource utilization (HRU), and costs among MCC pts receiving NCCN-recommended 1L regimens including CPIs and CT in the VHA. Methods: This is a retrospec

APA, Harvard, Vancouver, ISO, and other styles

48

Vaishampayan, Ulka N., Seongho Kim, Jaswinder Karwa, et al. "Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population." Journal of Clinical Oncology 37, no. 15_suppl (2019): e14136-e14136. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14136.

Full text

Abstract:

e14136 Background: NLR is reported to be a prognostic marker in multiple malignancies and has reported potential predictive value with ICI. We evaluated NLR as a predictor of response and time to treatment failure (TTF) in a phase I patient population treated with ICI. Methods: Regulatory approval was obtained. A retrospective chart review of patients treated on phase I trials with ICI based therapy at Karmanos Cancer Institute, was conducted. Data were collected on demographics, performance status, tumor type, response rate, TTF and NLR pre and post therapy. Associations with clinical benefit

APA, Harvard, Vancouver, ISO, and other styles

49

Nagaoka, Tomoyuki, Takeru Wakatsuki, Eiji Shinozaki, et al. "Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines." Journal of Clinical Oncology 35, no. 4_suppl (2017): 741. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.741.

Full text

Abstract:

741 Background: Recently it has been suggested that primary tumor location may have a clinical impact on the front line chemotherapies; namely, right-sided tumor benefit less from cytotoxic and targeted agents compared with left-sided tumor. Regorafenib and TAS 102 have recently emerged and the prognostic impacts of tumor location on these agents are unknown. Methods: Clinical information of patients who were administrated Regorafenib and/or TAS 102 was retrospectively collected. Patients’ demographics by tumor location were compared using Fisher’s exact test. Time to treatment failure (TTF),

APA, Harvard, Vancouver, ISO, and other styles

50

Smolenschi, Cristina, Emeline Colomba, Elie Rassy, et al. "NCOG-19. BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?" Neuro-Oncology 22, Supplement_2 (2020): ii133. http://dx.doi.org/10.1093/neuonc/noaa215.558.

Full text

Abstract:

Abstract Angiogenesis represents a hallmark of glioblastoma but most trials disappointed and failed to change the poor outcome of this disease. However, Bevacizumab (Bev) is widely used in clinical practice by expert oncologists due to experience or efficacy in real life.We retrospectively reviewed the use of Bev and its benefit in terms of Time to treatment failure (TTF), Overall Survival(OS), Objective Response Rate (ORR) and clinical benefit. METHODS: We analyzed two hundred and two patients treated at Gustave Roussy Cancer Campus with Bev until definitive failure for recurrent glioblastoma

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!